Frontlight ResearchEarly access
CompletedNo phase
Assessing and Promoting Resilience in Patients With Adult Congenital Heart Disease
Key facts
- Who runs it
- University of Washington
- Where
- Seattle, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 78 people enrolled
- Started
- 15 Mar 2023
- Ended
- 25 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Promoting Resilience in Stress Management (PRISM)
- Usual Care
- Record updated
- 15 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- adults with moderate or complex ACHD, stages B, C, or D as defined by the 2018 ACHD guidelines
- receive care in our health system
Who cannot take part
- diagnosis of another life-limiting illness
- inability to participate in study activities independently and in English
Where in United States
- University of WashingtonSeattle, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the feasibility and preliminary efficacy of the Promoting Resilience in Stress Management (PRISM) intervention in patients with adult congenital heart disease.
The 2 groups in the trial
- PRISM InterventionTreatment being tested
Subjects in this group will receive the PRISM intervention
Treatment: Promoting Resilience in Stress Management (PRISM)
- Usual CarePlacebo, for comparison
Subjects in this arm will receive usual care
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- A Randomized Trial of a Resilience-Building Intervention in Adult Outpatients With Congenital Heart Disease: Feasibility and Efficacy.JACC. Advances, 2025
- Rationale and design of a randomized controlled clinical trial of a resilience-building intervention in adults with congenital heart disease.Contemporary clinical trials, 2024
- Record updated
- 15 December 2025